is this 1-pg chat still open?, page-291

https://**promotion blocked**/wp-content/uploads/2021/10/Montu-640x360.jpg
The company is positioned with a first-mover advantage as Australia’s ‘cannabis ecosystem’, as it looks to benefit from strong industry tailwinds. Image: Supplied
Medicinal cannabis company Montu just grew annual revenues by 1,000% – now it’s returning to Birchal for more scale-up capital
Health & Biotech
October 29, 2021 | Special Report


SHARE

• https://**promotion blocked**/wp-content/themes/stockhead_lee_mic_v2/images/social-share/share-page.png
• https://**promotion blocked**/wp-content/themes/stockhead_lee_mic_v2/images/social-share/facebook.png
• https://**promotion blocked**/wp-content/themes/stockhead_lee_mic_v2/images/social-share/twitter.png
• https://**promotion blocked**/wp-content/themes/stockhead_lee_mic_v2/images/social-share/linkedin.png

The company is positioned with a first-mover advantage as Australia’s ‘cannabis ecosystem’, as it looks to benefit from strong industry tailwinds.
Australia’s cannabis sector has advanced from the “pioneer” stage, and is now on track to be a $1.7bn industry by 2023, Montu Managing Director Christopher Strauch says.
And amid those broader tailwinds, Montu is positioning as the market leader in medical cannabis as adoption rates rapidly accelerate.
Strauch caught up with * this week to discuss the company’s outlook, as it takes Expressions of Interest on the Birchal crowdfunding platform for a new capital raise to fund its next phase of growth.

Industry tailwinds

Montu has created Australia’s leading cannabis ecosystem, which streamlines the patient experience from end-to-end, and connects Australians to highly qualified doctors via Montu’s alternaleaf^TM telehealth platform.
In that context, Strauch said he’s had a front-row seat to the rapid uplift in the broader sector’s momentum over the past 12 months. However, it’s still early days.
“Medical cannabis is one of the fastest-growing sectors in the country, since more and more patients seek alternative therapies to common problems like pain and insomnia, without the side effects associated with conventional medications,” Strauch said.
As a measure of market growth, Strauch said patient approvals had grown around “10-fold” over the past 12 months, to a total of 170,000 approvals as at the end of September.



FYI